NorthWest Biotherapeutics Inc (NWBO)

[dpinvest]

The problem with analyzing her comment is that like everyone she is (or should be) blinded, so that using the term "everyone" about the trial is misguided. Like anybody else, all she should know is that the 240ish number of events milestone may not been reached (by October when the presentation was made), and without knowing more details one can only speculate that the SOC-only group may be doing well. That may be the case "as a group" but there may be not be much statistical significance within that data.

I guess all I am saying is that this is yet another intriguing NWBO clue that leaves bulls and bears clueless.